Aspect Biosystems to Present at the 42nd Annual J.P. Morgan Healthcare Conference

2024-01-04

细胞疗法

VANCOUVER, British Columbia--(BUSINESS WIRE)--Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform the treatment of disease, today announced that Founder and CEO Tamer Mohamed will present at the 42nd Annual J.P. Morgan Healthcare Conference, held January 8-11, 2024 in San Francisco, CA.

The presentation will take place on Thursday, January 11, 2024, at 9:30 a.m. PT.

About Aspect Biosystems

Aspect Biosystems is a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform the treatment of currently incurable diseases. Aspect is creating these next-generation cell therapies by applying its full-stack tissue therapeutic platform, which combines the company’s proprietary bioprinting technology, therapeutic cells, biomaterials, and computational design. Aspect’s bioprinted tissue therapeutics are designed to replace, repair, or supplement biological function inside the body. The company’s current therapeutic pipeline is focused on metabolic and endocrine diseases such as diabetes, obesity, and congenital liver disorders. Learn more at www.aspectbiosystems.com.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构